A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

New England Journal of Medicine
December 14, 2017  Vol. 377 No. 24
http://www.nejm.org/toc/nejm/medical-journal

Original Article
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
Lars Ostergaard, M.D., Ph.D., Timo Vesikari, M.D., Ph.D., Judith Absalon, M.D., M.P.H., Johannes Beeslaar, M.D., Brian J. Ward, M.D., C.M., Shelly Senders, M.D., Joseph J. Eiden, M.D., Ph.D., Kathrin U. Jansen, Ph.D., Annaliesa S. Anderson, Ph.D., Laura J. York, Ph.D., Thomas R. Jones, Ph.D., Shannon L. Harris, Ph.D., Robert O’Neill, Ph.D., David Radley, M.S., Roger Maansson, M.S., Jean-Louis Prégaldien, M.S., John Ginis, B.S., Nina B. Staerke, M.D., and John L. Perez, M.D., for the B1971009 and B1971016 Trial Investigators*
N Engl J Med 2017; 377:2349-2362 December 14, 2017
DOI: 10.1056/NEJMoa1614474
Background
MenB-FHbp is a licensed meningococcal B vaccine targeting factor H–binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus.